Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients

Inclusion Criteria: * Man or woman age 18-75 years * SARS-CoV2 positive as confirmed by SARS-CoV2 RT-PCR Test * Diagnosed with pnumonia as confirmed by chect radiography and history of fever, coug with one of the following symptoms: RR \> 30x per minute, SaO2 93%, FaO2/FiO2 300 mmHg * Voluntarily joined the clinical trial and has signed the informed consent form Exclusion Criteria: * Pregnant and lactating woman * Patient who are diagnosed or have history of tumor and cancer * Patient whose mother or sister are diagnosed with breast or ovarian cancer * Level of SGPT/ALT is ≥ 5 times upper limit from normal value * Level of eGFR is \< 30 ml/min * Reluctant to sign informed consent and unwilling to take the required tests * Require invasive ventilation * Shock * Organ failure * Currently involve in other clinical trial, or join another clinical trial in the last 3 months